EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System (Evolution Stent System) for the Treatment of a De Novo Atherosclerotic Lesion.

Trial Profile

EVOLVE: A Prospective Randomized Multicenter Single-blind Non-inferiority Trial to Assess the Safety and Performance of the Evolution Everolimus-Eluting Monorail Coronary Stent System (Evolution Stent System) for the Treatment of a De Novo Atherosclerotic Lesion.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 01 May 2016 Status changed from active, no longer recruiting to completed.
    • 19 May 2015 Long term data published in the Boston Scientific Corporation media release.
    • 21 May 2014 Positive 3-year follow-up data have been published in a Boston Scientific media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top